Research Summaries - Oncology Matrix

Research Summary: KRAS G12C mutations occur in a substantial subset of advanced non-small cell lung

Research Summary: Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are B-cell malignancies that

Research Summary: Capivasertib is a potent, selective inhibitor of all three protein kinase B (AKT1/2/3)

Research Summary: Covalent Bruton tyrosine kinase (BTK) inhibitors have become the preferred treatment for chronic

Research Summary: Accurate prognostic assessment in patients with cutaneous melanoma is essential as it is

Research Summary: Cutaneous melanoma is a significant public health concern, as it is the fifth

Research Summary: Estrogen receptor–positive (ER+) breast cancer is primarily driven by signaling through estrogen receptor

Research Summary: Ciltacabtagene autoleucel (cilta-cel) is a B-cell maturation antigen (BCMA)–targeted chimeric antigen receptor T-cell

Research Summary: The EMBER-3 trial1 was a Phase III, open-label study that evaluated imlunestrant, a

Research Summary: For patients with heavily pretreated relapsed/refractory multiple myeloma (RRMM), prior reports have shown

Research Summary Chimeric antigen receptor T-cell (CAR-T) therapy is typically administered in the inpatient setting,

Research Summary This study1 evaluated the Medicare cost impact of choosing among covalent Bruton tyrosine

Research Summary In this randomized, controlled, Phase III study,1 patients with resectable, epidermal growth factor

Research Summary Advances in T-cell redirecting therapy (TCRT), which includes chimeric antigen receptor T-cell (CAR-T)

Research Summary Ciltacabtagene autoleucel (cilta-cel) is a second-generation autologous chimeric antigen receptor T-cell (CAR-T) therapy

The phosphoinositide 3-kinase (PI3K)-AKT signaling pathway is a key regulator of cell growth, survival, and

Research Summary Bruton tyrosine kinase (BTK) inhibitors have improved the treatment landscape of chronic lymphocytic

Research Summary Concurrent chemoradiotherapy (cCRT) followed by adjuvant durvalumab is the standard first-line treatment for

Research Summary Chimeric antigen receptor T-cell (CAR-T) therapy is an effective treatment option for relapsed/refractory

Research Summary: Sentinel lymph node biopsy (SLNB) is a standard procedure for staging and management